Exelixis, Inc. is a genomic-based drug discovery company located in Alameda, California, and a Product Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for myeloid thyroid cancer with clinical activity in several other types of metastatic cancer. Founded in 1994, The Scientific Founders spyridon Artavanis-Tsakonas, at Yale University at the time, and Corey Goodman and Jerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The action plan was to use typical organisms (fruit flies, nematodes, zebras) and functional genomics to identify biological pathways and objectives that could be exploited in agriculture and medicine. It is finally established on branch, Excelxes plant sciences, for the agricultural work. By 2000, it had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The public company went that year, after withdrawing its offer the previous week. Raised $118 million in the Had market. In 2002 the company signed a broad alliance with GSK to discover new drugs in the areas of cancer, inflammatory diseases and blood vessels. GSK paid $30 million in cash, purchased $14 million of stocks at twice the market price, committed to providing Excelsius with $90 million in research funding; and offered to finance a loan of up to $85 million. By 2002, the company had limited its internal efforts to cancer, and its strategy had stabilized the discovery and development of drugs. That can prevent small target groups of tyrosine kinases that they need to form cancer, growth, and sherchance. Groups of TKs have been identified through their previous work in functional genomics. This approach was controversial at the time; most companies are trying to selectively target only one protein in their discovery efforts. In 2006 Exelixis partnered with Daiichi Sankyo on compounds targeting metal receptors; Isacerinon was part of this cooperation. In 2007, the company partnered the MEK inhibitor program with Genentech. Cobimetinib (at the time XL-518) was part of this collaboration. Axlsis had introduced IND on xl-518 prior to the partnership, committed to funding and managing the phase i trial, and retained the rights to participate in its marketing in the United States. In 2008, the company partnered with its main candidate for cancer drugs, XL-184 (which will be called Capozantinib) and another cancer filter, XL-281, with Bristol-Myers Squibb; BMS restored rights to XL-184 to Exelixis in 2010 and returned rights to another pharmaceutical candidate in 2011.In 2010, scangos left as CEO at Biogen and appointed Michael M. Morrissey as president and CEO; Morrissey joined the company in 2000 as vice president of Discovery Research. At that time the company had eight drugs in clinical trials. Exelixis was first approved in 2012, when capothaninib was approved for myeloma thyroid cancer, an orphan index. Approved in Europe in 2014.Exelixis invested heavily in exploring cabozantinib in other cancers, betting on the future of the company On drugs. In 2014 the drug failed in the third stage trial of prostate cancer, and the company discharged 70% of its employees. In 2015 Genentech and Exelixis won FDA approval for cobimetinib for certain forms of skin cancer. In March 2016, Exelixis was licensed for Ibsen Rights worldwide (outside the United States, Canada and Japan) to market Kaposantenib. In April 2016, the FDA granted approval to market the pill formula as a second-line treatment for kidney cancer and the same was approved in Europe in October of that year. In December 2017, the FDA granted approval for the use of capozantenib to treat first-line kidney cancer, and in May 2018 first-line treatment was approved in Europe.